Randomized controlled trial of pilocarpine hydrochloride for the moderation of oral mucositis during autologous blood stem cell transplantation

Lockhart, Peter B.; Brennan, Michael T.; Kent, M. Louise; Packman, Charles H.; Norton, H. James; Fox, Philip C.; Frenette, Gary

doi:10.1038/sj.bmt.1704820

Cited by 28 publications

(10 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…or combination chemotherapy (ifosfamide, carboplatin and etoposide) plus autologous HSCT (Oblon et al , 1997). Pilocarpine has also been suggested to reduce mucositis (Awidi et al , 2001) but a prospective, double‐blinded, randomized, placebo‐controlled trial in oral mucositis during autologous HSCT showed no benefit (Lockhart et al , 2005).…”

Section: Prophylaxis Of Mucositismentioning

confidence: 99%

Oral mucositis

2006

View full text Add to dashboard Cite

Mucositis and xerostomia are the most common oral complications of the non-surgical therapy of cancer. Mucositis, a common sequel of radio- (DXR), chemo-(CXR) and radiochemo-therapy in patients with cancer, or patients requiring haemopoietic stem cell transplants (HSCT), has a direct and significant impact on the quality of life and cost of care, and also affects survival--because of the risk of infection. Apart from dose reduction, preventive and treatment options for mucositis are scarce, although multiple agents have been tested. Evidence suggests that cryotherapy, topical benzydamine and amifostine might provide some benefit in specific situations. The recombinant human keratinocyte growth factor Palifermin (Kepivance) was recently approved as a mucositis intervention in patients receiving conditioning regimens before HSCT for the treatment of haematological malignancies. A number of mechanistically based interventions are in various stages of development. Unfortunately, many other approaches have not been rigorously tested. This paper reviews the clinical features, prevalence, diagnosis, complications, pathogenesis, prophylaxis and management of mucositis.

show abstract

Section: Prophylaxis Of Mucositismentioning

confidence: 99%

Oral mucositis

2006

View full text Add to dashboard Cite

show abstract

“…Saliva plays a major role in oral homeostasis, notably through salivary immunoglobulin A (Epstein et al 2002); however, surprisingly, an attempt to increase production by pilocarpine hydrochloride in cases of decreased or absent saliva (ie, xerostomia) failed to moderate oral mucositis (Lockhart et al 2005). …”

Section: Message Generationmentioning

confidence: 99%

Oral mucositis induced by anticancer treatments: physiopathology and treatments

Lionel¹,

Lonchay²,

André³

et al. 2006

Therapeutics and Clinical Risk Management

View full text Add to dashboard Cite

Oral mucositis is a frequent and devastating side effect of anticancer treatments. It impairs the patient's quality of life and also can be life threatening because severe infections and delayed or incomplete anticancer treatments may result. This problem has been largely overlooked and underestimated in the past. However, recently studies have been performed to precisely identify the epidemiology, cost, consequences, physiopathology, and treatments of oral mucositis. Clinical guidelines have recently been published to help the daily management of this frequent complication. In addition, some innovative new drugs, including palifermin, have been developed to prevent and treat this major side effect of cancer treatments. In this paper we summarize the recent developments of oral mucositis management.

show abstract

“…66 The topical application of chlorhexidine, 67 GM-CSF, 67 the salivary production stimulator pilocarpine, 68 and histamine gel 69 is not recommended for the prophylaxis of OM given the reported lack of efficacyof these agents. Moreover, no benefits have been found from the use of the amino acid glutamine in the setting of SCT.…”

mentioning

confidence: 99%

Mucositis in patients with hematologic malignancies: an overview

Niscola¹,

Romani²,

Cupelli³

et al. 2007

Haematologica

View full text Add to dashboard Cite

Decision Making and Problem SolvingMucosal barrier injury (mucositis) is a common complication of many treatments used in hematologic malignancies, affecting most patients whose neoplasms are treated with intensive chemotherapy, and virtually all those receiving myeloablative conditioning regimens prior to hematopoietic stem cell transplantation. Mucositis has been identified as a critical risk factor for infections and is a major driver of analgesic and total parenteral nutrition use. Patients with this complication require careful analgesic therapy, additional nursing care and longer hospitalization. To date, the measures to prevent and treat this potentially devastating complication are inadequate and limited to the control of pain, infections, bleeding and nutrition. Nevertheless, in the last decade, a better insight into the pathogenesis of the mucosal damage has led to the development of novel therapeutic options which potentially could allow a targeted approach to mucositis.Key words: mucositis, pain, hematologic malignancies, graft-versus-host disease, hematopoietic stem cell transplantation.

show abstract

Randomized controlled trial of pilocarpine hydrochloride for the moderation of oral mucositis during autologous blood stem cell transplantation

Cited by 28 publications

References 68 publications

Oral mucositis

Oral mucositis

Oral mucositis induced by anticancer treatments: physiopathology and treatments

Mucositis in patients with hematologic malignancies: an overview

Contact Info

Product

Resources

About